Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Post-Mkt 12-05 19:12:36 EST

86.11

+1.45

+1.71%

盘后87.73

+1.63+1.89%

18:07 EST

High86.39	Low83.60	Vol644.15K
Open85.27	D1 Closing84.66	Amplitude3.30%
Mkt Cap9.06B	Tradable Cap7.48B	Total Shares105.19M
T/O55.04M	T/O Rate0.74%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":86.105,"timestamp":1764968400000,"preClose":84.66,"halted":0,"volume":644152,"hourTrading":{"tag":"盘后","latestPrice":87.73,"preClose":86.105,"latestTime":"18:07 EST","volume":12528,"amount":1078726.69728,"timestamp":1764976052375},"delay":0,"floatShares":86875270,"shares":105188217,"eps":0.873455,"marketStatus":"Post-Mkt","change":1.445,"latestTime":"12-05 19:12:36 EST","open":85.27,"high":86.39,"low":83.595,"amount":55038060.32432,"amplitude":0.033014,"askPrice":87.78,"askSize":22,"bidPrice":84.44,"bidSize":23,"shortable":3,"etf":0,"ttmEps":0.873455,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764982800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":84.66,"preHourTrading":{"tag":"盘前","latestPrice":85.3,"preClose":84.66,"latestTime":"09:23 EST","volume":108,"amount":9501.47928,"timestamp":1764944630191},"postHourTrading":{"tag":"盘后","latestPrice":87.73,"preClose":86.105,"latestTime":"18:07 EST","volume":12528,"amount":1078726.69728,"timestamp":1764976052375},"volumeRatio":0.811784,"impliedVol":1.12,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2588076560","title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588076560","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588076560?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:15","pubTimestamp":1764810909,"startTime":"0","endTime":"0","summary":"Joseph K. Belanoff, Chief Executive Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL37zBvt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1559883803.SGD","BK4007","LU0566484027.USD","CORT"],"gpt_icon":0},{"id":"2587308397","title":"Corcept Therapeutics (CORT): Assessing Valuation After Revenue Outlook Revision and Growth in Korlym Prescriptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2587308397","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587308397?lang=en_us&edition=fundamental","pubTime":"2025-11-29 04:21","pubTimestamp":1764361266,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) has adjusted its revenue outlook for 2025, citing capacity constraints with a previous specialty pharmacy vendor. This adjustment comes as new prescriptions for Korlym continue to increase in its hypercortisolism segment.\nSee our latest analysis for Corcept Therapeutics.\nCorcept’s revenue guidance revision comes after strong momentum in both its core business and share price. Despite recent insider selling and mixed third-quarter results, the stock has delivered a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-assessing-valuation-after-revenue","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-assessing-valuation-after-revenue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"2586293250","title":"Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586293250","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586293250?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:23","pubTimestamp":1764195821,"startTime":"0","endTime":"0","summary":"William Guyer, Chief Development Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL7shfDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Chief Development Officer William Guyer Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","CORT","BK4532","LU0566484027.USD","BK4007"],"gpt_icon":0},{"id":"2586204904","title":"Corcept Therapeutics Price Target Maintained With a $145.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2586204904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586204904?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:14","pubTimestamp":1764072840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2025 07:14 ET (12:14 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"gpt_icon":0},{"id":"2581834048","title":"Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581834048","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581834048?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:10","pubTimestamp":1762553437,"startTime":"0","endTime":"0","summary":"William Guyer, Chief Development Officer of Corcept Therapeutics Incorporated, reported a disposal of common shares of Corcept Therapeutics Incorporated. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5LlC8V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Development Officer William Guyer Reports Disposal of Corcept Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","CORT","BK4007"],"gpt_icon":0},{"id":"2581840670","title":"Corcept Therapeutics CEO Joseph K. Belanoff Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581840670","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581840670?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:58","pubTimestamp":1762390711,"startTime":"0","endTime":"0","summary":"Joseph K. Belanoff, Chief Executive Officer and Director of Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL7Hsg4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT","LU0566484027.USD","BK4532","LU1559883803.SGD","BK4007"],"gpt_icon":0},{"id":"2581084062","title":"Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Corcept Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084062","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581084062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:57","pubTimestamp":1762390635,"startTime":"0","endTime":"0","summary":"Sean Maduck, Officer at Corcept Therapeutics Incorporated, reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1TSLC7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Sean Maduck, President of Corcept Endocrinology, Reports Disposal of Corcept Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","LU0566484027.USD","LU1559883803.SGD","BK4532"],"gpt_icon":0},{"id":"2581743667","title":"H.C. Wainwright Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581743667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581743667?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:56","pubTimestamp":1762358183,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics today and set a price target of $145.00. According t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"1184309320","title":"Stock Track | Corcept Therapeutics Soars 5.61% as Analyst Maintains Buy Rating Amid Recent Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184309320","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184309320?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:29","pubTimestamp":1762356599,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (CORT) surged 5.61% in Wednesday's pre-market trading session, rebounding from a recent pullback as investors reacted to positive analyst sentiment and reassessed the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581727938","title":"Truist Financial Sticks to Their Buy Rating for Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727938","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581727938?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:57","pubTimestamp":1762347451,"startTime":"0","endTime":"0","summary":"Truist Financial analyst Joon Lee maintained a Buy rating on Corcept Therapeutics today. The company’s shares closed yesterday at $71.10. Lee cover...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"gpt_icon":0},{"id":"1149507846","title":"Stock Track | Corcept Therapeutics Plunges 9.83% Pre-market on Q3 Revenue Miss and Lowered 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1149507846","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149507846?lang=en_us&edition=fundamental","pubTime":"2025-11-05 17:22","pubTimestamp":1762334549,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 9.83% in pre-market trading on Wednesday, following the release of its disappointing third-quarter financial results and reduced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581872525","title":"Does Corcept Therapeutics’ Recent 21% Pullback Signal a Fresh Opportunity in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581872525","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581872525?lang=en_us&edition=fundamental","pubTime":"2025-11-05 15:46","pubTimestamp":1762328772,"startTime":"0","endTime":"0","summary":"Wondering if Corcept Therapeutics is still a smart buy or if the market has gotten ahead of itself? If you’re curious about getting real value from your investments, this could be the stock to watch.\nThe past year has been good to Corcept, with the stock climbing 31.1% over 12 months and an eye-catching 42.3% year to date. However, recent weeks have seen a pullback of -20.9% for the month and -1.3% in the past week.\nThese price swings come as a result of heightened investor attention, driven...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-recent-21-pullback-signal-a-fresh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/does-corcept-therapeutics-recent-21-pullback-signal-a-fresh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT","BK4532","LU0566484027.USD","DCF","BK4007","LU1559883803.SGD"],"gpt_icon":0},{"id":"1156587177","title":"Stock Track | Corcept Therapeutics Plunges 7.24% After Q3 Revenue Miss and Lowered Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1156587177","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156587177?lang=en_us&edition=fundamental","pubTime":"2025-11-05 09:16","pubTimestamp":1762305405,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.24% on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known for its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581672047","title":"GUIDANCE: (CORT) Corcept Therapeutics Modifies 2025 Revenue Range To $800M-$850M, vs. FactSet Est of $852.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581672047","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581672047?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:51","pubTimestamp":1762293107,"startTime":"0","endTime":"0","summary":"GUIDANCE: (CORT) Corcept Therapeutics Modifies 2025 Revenue Range To $800M-$850M, vs. FactSet Est of $852.6M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"gpt_icon":0},{"id":"2581676720","title":"Earnings Flash (CORT) Corcept Therapeutics Posts Q3 EPS $0.16, vs. FactSet Est of $0.13 by Four Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2581676720","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581676720?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:48","pubTimestamp":1762292882,"startTime":"0","endTime":"0","summary":"Earnings Flash (CORT) Corcept Therapeutics Posts Q3 EPS $0.16, vs. FactSet Est of $0.13 by Four Analysts","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CORT"],"gpt_icon":0},{"id":"2581476769","title":"Corcept Therapeutics misses Q3 revenue expectations, modifies 2025 revenue forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2581476769","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581476769?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:43","pubTimestamp":1762292591,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics misses Q3 revenue expectations, modifies 2025 revenue forecastOverviewCorcept Q3 2025 revenue of $207.6 mln, missed analyst expectationsNet income for Q3 2025 decreased to $19.7 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG1ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","CORT","LU0566484027.USD","LU1559883803.SGD"],"gpt_icon":0},{"id":"1136659010","title":"Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Q3 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1136659010","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136659010?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:36","pubTimestamp":1762292202,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"1131454549","title":"Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Mixed Q3 Results and Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1131454549","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131454549?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:35","pubTimestamp":1762292148,"startTime":"0","endTime":"0","summary":"Shares of Corcept Therapeutics (NASDAQ: CORT) tumbled 7.17% in after-hours trading on Tuesday following the release of the company's third-quarter financial results. The biopharmaceutical firm, known...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CORT"],"gpt_icon":0},{"id":"2581769008","title":"Corcept Therapeutics reports third quarter revenue of $207.6 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769008?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:07","pubTimestamp":1762290455,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics reported third quarter 2025 revenue of $207.6 million, up from $182.5 million in the same period of 2024. Net income for the quarter was $19.7 million, compared to $47.2 million in the third quarter of 2024. Operating expenses rose to $197.4 million from $135.9 million a year earlier, reflecting increased spending related to upcoming product launches. Cash and investments totaled $524.2 million as of September 30, 2025. The company updated its 2025 revenue guidance to a range of $800-$850 million. Business developments included expanding oncology programs to new studies in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers in combination with chemotherapy, as well as studies of solid tumors in combination with immunotherapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes on","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2bGGZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","CORT","LU0566484027.USD","LU1559883803.SGD"],"gpt_icon":0},{"id":"2581799769","title":"BRIEF-Corcept Therapeutics Q3 EPS USD 0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2581799769","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581799769?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290349,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Therapeutics Q3 EPS USD 0.16\n\n\nNov 04 (Reuters) - Corcept Therapeutics Q3 revenue USD 207.638 million vs. IBES estimate USD 223.8 million.\n\nQ3 net income USD 19.668 million\noutlook FY revenue USD 800-850 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX4FEB58:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0566484027.USD","CORT","LU1559883803.SGD","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.0609},{"period":"1month","weight":0.1907},{"period":"3month","weight":0.2206},{"period":"6month","weight":0.2164},{"period":"1year","weight":0.3913},{"period":"ytd","weight":0.6801}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.016463},{"month":2,"riseRate":0.428571,"avgChangeRate":0.014054},{"month":3,"riseRate":0.761905,"avgChangeRate":0.141286},{"month":4,"riseRate":0.52381,"avgChangeRate":-0.001402},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.454545,"avgChangeRate":0.055992}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction